FindTrial
Sign In

The role of acetylation modification of TFAM by GCN5L1 in squamous cell carcinoma and its intervention strategy by using the comprehensive information management platform for lung cancer

The role of acetylation modification of TFAM by GCN5L1 in squamous cell carcinoma and its intervention strategy by using the comprehensive information management platform for lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046663
Enrollment
Unknown
Registered
2021-05-26
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell carcinoma of lung

Interventions

LUSC group:No

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Pathological diagnosis of lung squamous cell carcinoma.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors; 2. Patients with immune diseases; 3. Patients with low KPS score.

Design outcomes

Primary

MeasureTime frame
Basic information;Tumor staging;Image data;Laboratory index;—

Countries

China

Contacts

Public ContactSheng Wei

Shandong Provincial Hospital

shengwei39@sina.com+86 15168889186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026